source
- Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.BioSpace · 2h ago↗ source
- Four biotech firms secure Series B funding and open new hiring opportunitiesBiotech companies that closed Series B financing rounds this year are actively recruiting as they expand their operations. Atavistik Bio, based in Cambridge, Massachusetts, announced a $40 million…